A detailed history of M&R Capital Management Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, M&R Capital Management Inc holds 625 shares of VRTX stock, worth $296,350. This represents 0.07% of its overall portfolio holdings.

Number of Shares
625
Previous 525 19.05%
Holding current value
$296,350
Previous $219,000 33.33%
% of portfolio
0.07%
Previous 0.05%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 02, 2024

BUY
$392.81 - $485.53 $39,281 - $48,553
100 Added 19.05%
625 $292,000
Q1 2024

Apr 02, 2024

BUY
$407.69 - $446.08 $122,714 - $134,270
301 Added 134.38%
525 $219,000
Q4 2023

Jan 02, 2024

BUY
$343.0 - $410.68 $68,600 - $82,136
200 Added 833.33%
224 $91,000
Q4 2022

Jan 11, 2023

BUY
$285.76 - $321.48 $6,858 - $7,715
24 New
24 $0
Q4 2020

Jan 05, 2021

SELL
$207.01 - $276.09 $20,701 - $27,608
-100 Closed
0 $0
Q2 2017

Aug 15, 2017

BUY
N/A
100
100 $15,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track M&R Capital Management Inc Portfolio

Follow M&R Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of M&R Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on M&R Capital Management Inc with notifications on news.